PCSK9 inhibitors: the next frontier in low-density lipoprotein lowering

Metabolic Syndrome and Related Disorders
Ishwarlal Jialal, Shailendra B Patel

Abstract

The discovery and elucidation of the role of the low-density lipoprotein receptor (LDL-R) in familial hypercholesterolemia (FH) ushered in the statin group of drugs. These drugs, in addition to lowering low-density lipoprotein cholesterol (LDL-C), result in a significant reduction in cardiovascular events (CVE) and mortality. Recently, a gain-of-function mutation in another protein, proprotein convertase subtilisin/kexin type 9 (PCSK9), was reported to result in a FH phenotype by promoting degradation of the LDL-R. More importantly, loss-of-function mutations in the same gene resulted in low LDL-C and a reduction in CVE, making this an enticing target for drug development. Numerous strategies have been developed to target PCSK9, the most successful being monoclonal antibodies (mAbs) that bind PCSK9. These mAbs have been shown to reduce LDL-C around 50% as either monotherapy with diet or in combination with statin therapy. In this short perspective, we discuss the biochemistry and biology of PCSK9 in relation to lipid metabolism and the promising studies in humans demonstrating a substantial reduction in LDL-C with relative good short-term safety of PCSK9 mAbs.

References

Oct 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·T L InnerarityS M Grundy
Apr 17, 1999·American Journal of Human Genetics·M VarretC Boileau
Apr 15, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·S C HuntM E Samuels
Jan 29, 2003·Proceedings of the National Academy of Sciences of the United States of America·Nabil G SeidahMichel Chretien
May 6, 2003·Nature Genetics·Marianne AbifadelCatherine Boileau
Jan 29, 2005·Proceedings of the National Academy of Sciences of the United States of America·Kara N MaxwellJan L Breslow
Aug 2, 2005·Cell Metabolism·Alan D Attie, Nabil G Seidah
Mar 24, 2006·The New England Journal of Medicine·Jonathan C CohenHelen H Hobbs
Nov 1, 2008·Journal of Lipid Research·Michael S Brown, Joseph L Goldstein
Jan 1, 2014·Archives of Cardiovascular Diseases·Michel Farnier
Jan 16, 2014·Annual Review of Medicine·Evan A Stein, Frederick Raal
Apr 1, 2014·The New England Journal of Medicine·Dirk J BlomUNKNOWN DESCARTES Investigators
Jun 25, 2014·Nature Reviews. Cardiology·Razvan T Dadu, Christie M Ballantyne

❮ Previous
Next ❯

Methods Mentioned

BETA
antisense oligonucleotides

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
Ahmet AvciBülent Behlül Altunkeser
Expert Opinion on Therapeutic Targets
Nabil G Seidah
Nature Reviews. Cardiology
Razvan T Dadu, Christie M Ballantyne
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Michel Farnier
Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Li ShenShuiping Zhao
© 2022 Meta ULC. All rights reserved